Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Oncology Boards > Leukemia + Canine LSA (mostly chemo) > Flashcards

Leukemia + Canine LSA (mostly chemo) Flashcards

1
Q

What prognostic factors were identified for dogs with acute leukemias? (Novacco VCO 2015)

A

Normal neutrophil count prolonged survival (compared to penic or philic dogs) Anemia (worse if present 9d vs 60d) Including cytarabine improved survival

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What staining can help to differentiated AML from LSA or LSA? (Stokol Vet Clin Path 2015)

A

ALP - activity in 100%, strong in 64% vs. no ALP in LSA and only weak ALP in 21% of ALL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What two markers may help to differentiate CLL from ALL (Vet Immuno and Immuno 2014 and 2013)

A

CD44 hyaluronan receptor and higher c-kit expression (levels of mRNA for both) in ALL vs. CLL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

In humans ____-cell CLL is most common; in dogs ____-cell CLL is most common

A

Humans B-cell Dogs T-cell (70-75%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What were the phenotyptes for cats with ALL (Tomiyasu JSAP 2018

A

B cell (n=4), T cell (n=1) CD21+CD8+ (n=1)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What was the MST for cats with ALL treated with cytotoxic chemotherapy (Tomiyasu JSAP 2018)

A

PR in 2, MST 55 only 4/6 cats in study were treated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What were the most common clinical signs in dogs with AML (Davis VCO 2018)

A

Inappetence (66%), lethargy (57%), peripheral lymphadenopathy (74%) tachypnea (62%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What were the hematologic findings in dogs with AML? (Davis VCO 2018)

A

circulating blasts (85%, median count 35.7k), anemia (median 34%), thrombocytopenia (median 57k)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What was the MST for dogs with AML? What improved survival? (Davis VCO 2018)

A

MST 19d. Chemo+pred improved survival: chemo MST 58d. vs. pred alone 25d vs. symptomatic care alone 1d

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What were the characteristics of cats with Bcell lymphocytosis? (Rout JVIM 2019)

A

Younger cats Polyclonal + lower counts Long survival (same as cats with heterogenous lymphocytosis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What were the characteristics of cats with CD4+ T cell lymphocytosis (Rout JVIM 2019)

A

Most common type identified MST 752d Shorter ST w/ abdominal lymphadenopathy and/or Gi involvement or if female

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What was the mst for cats with CD4/CD8 T cell lymphocytosis (Rout JVIM 2019)

A

271d

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What was the MST for cats with CD5 low T cell lymphocytosis

A

27.5d

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What were the most common clinical signs for cats with CLL? (Campbell VCO 2012)

A

Weight loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What was the ORR and OST for cats treated with chemo for CLL? (Campbell VCO 2012)

A

most treated with pred/chlorambucil, some had CHOP ORR 88% OST 14.4mo (median remission duration = 15.7mo)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What breeds of dogs were more likely to have B cell CLL? (Bromberek JVIM 2016)

A

Small breed dogs had increased odds English Bulldogs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What is the unique presentation for English Bulldogs with CLL? (Bromberek JVIM 2016)

A

B cell, lower expression of MHCII and CD25 Younger at presentation - median = 6yr

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What was the rate of peripheral lymphadnopathy or splenomegaly for dogs with Bcell CLL? (Bromberek JVIM 2016)

A

50%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What was the rate of Richter’s syndrome in dogs with CLL? (Comazzi VCO 2015)

A

5.2% of cases (8/153) - mixed phenotype (n=2 T cell, n = 6 B cell)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What were the clinical signs for dogs presenting with Richter’s syndrome? (Comazzi VCO 2015)

A

LN swelling, coughing, vomiting, neuro signs and weight loss

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What was the MST after the onset of Richter’s syndrome in dogs? (Comazzi VCO 2015)

A

MST 41d

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is the prognostic significance for immunophenotype in dogs with CLL? (Comazzi JVIM 2011)

A

T cell MST 930d > B cell 480d > atypical 22d

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What was a poor prognostic factor for dogs with T cell CLL? (Comazzi JVIM 2011)

A

anemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What was prognostic factor for dogs with B cell CLL? (Comazzi JVIM 2011)

A

older dogs did better than younger dogs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

What was prognostic for dogs with CD8+ lymphocytosis? (Williams JVIM 2008)

A

<30k lymphs MST 1098d >30k lymphs MST 131d Overall MST 474d

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

What was the rate of copy number aberrations (CNA) and which was most common in a dog with BCR-ABL positive CML? (Culver Vet Path 2013)

A

22 CNAs present (measured via FISH)

Trisomy of Chromosome 7 (CFA7) most common (42% of leukemic cells); BCR-ABL present in 17.3% of leukemic cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

After one week of chemotherapy, what was the change in CNAs identified in a dog with BCR-ABL positive CML? (Culver Vet Clin Path 2013)

A

Trisomy 7 (CFA7) decreased from 42% to 2%

BCR-ABL decreased from 17.3% to 3.3%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What is a unique findings that occampanies most equine acute leukemia? (Cooper vet path 2017)

A

frequent inflammation - 10/20 horses had increased acute phase proteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What was the rate of mortality associated with BMT in dogs with B cell LSA? (Wilcox JVIM 2012)

A

8.3% mortality

1 dog developed pulmonary fibrosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

What was the DFI and OST for dogs treated with BMT for BV cell LSA? (Wilcox JVIM 2012)

A

DFI 271d (9mo)

OST 463d (15.4mo)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

What were the hematologic changes after total body RT + BMT in dogs with lymphoma? How did this change over time? (Escobar Vet Path 2011)

A

Grade 4 neutropenia and thrombocytopenia in all dogs

All dogs had >500 neutrophils by day 12, but thrombocytopenia persisted for many weeks

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

What effect did combining imatinib with DOX have on canine B cell LSA cell lines? (Chen Vet J 2019)

A

Imat. sig. potentiated sensitivity of dox in P-glycoprotein overexpressing doxo resistant cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

mPFS for dogs with T cell LSA (or presumed T cell based on hypercal) treated with modified MOPP vs. L-CHOP as first line therapy? (Angelo JSAP 2019)

A

L-CHOP 133d

modified MOPP (Must/vinc only on day 0, not repeated in cycle) 97d (not stat different)

goldens had longer pFS for CHOP than MOPP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

What was the protocol for 12-wk CHOP and how did the PFS and MST compare to CHOP19? (Vos VCO 2019) **committee member**

A

12 wk = vinc, ctx, dox repeat w/o wk off (more dose intense for doxo and ctx but less for vinc)

CHOP19 = mPFS 245 (8.2mo), MST 347d (11.6mo)

CHOP12 = mPFS 141d (4.7mo) MST 229d (7.6mo)

No stat sig different

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

What was the ORR, mPFI and MST for dogs treated with CMOP (mixo for doxo) vs. CHOP as first line for LSA? (Marquaardt JAVMA 2019) **Committee member**

A

CMOP: 100% CR, mPFI 165d (5.5mo), MST 234d (7.8mo)

CHOP: 97.4% CR, mPFI 208d (6.9mo), MST 348d (11.6mo)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

What was the ORR and duration of response to mito/dacarbazine given together to dogs with LSA? (Intile JAAHA 2018)

A

ORR 34%, median duration 97d

Dogs with previous CR to L-CHOP had better response (23% vs. 11%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

What were the rate and severity of AEs for dogs given mito/dacarbazine together for LSA? (Intile JAAHA 2018)

A

Grade 3-4 neutropenia in at least 45%

5% hospitalization even though prophylactic TMS given

GI tox uncommon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

What was the response to single agent VBL to treatment naive LSA w/o steroids or other chemo in dogs? (Harding VCO 2018)

A

2mg/m2 = 1/14 PR (7%)

2.5mg/m2 = 3/5 PR (60%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

What was the rate of CR and the mPFS for these dogs that were treated with LOPP for T cell LSA as a first line protocol? (Morgan VCO 2018)

A

29/35 CR (83%), PFS 509d

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

What was the rate of AEs for dogs with T cell LSA treated with LOPP as a first line therapy? (Morgan VCO 2018) (This LOPP = CCNU/vinc day 1, procarb/pred day 2-15, vinc d 15, repeat q4wk

A

70% of AEs = grade 1-2 but 11% hosp. during protocol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

What was the overall mPFS, 1yr PFS rate and MST for dogs treated with LOPP as a first line for T cell LSA? Morgan VCO 2018)

A

mPFS 431d (14.4mo), 1yr PFS 54%

MST 507d (16.9mo)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

How did using a pretreatment neut cutoff of 1.5k compare to 2k or 2.5k for dogs underoing CHOP? (Fournier JVIM 2018)

A

No difference in toxicity, but less treatment delays with 1.5k group (7% compared to 10 and 16%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

What was the outcome for elderly dogs (≥14yr) treated with chemo for multicentric LSA (JAVMA 2018)

A

MST 202d (6.7mo) 1-yr and 2-yr survival 31% and 5%

Do not need to adjust treatment for elderly dogs (27% AEs grade 3 or worse)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

What is RV1001? (Gardner PLoS One 2018)

A

potent selective inhibitor of PI3K delta (inhibits pAKT); given orally

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

What was the ORR to RV1001 for dogs with LSA? What were the main AEs? (Gardner plos one 2018)

A

Phase I = 62% (3CR, 10PR)

Phase II = 77%

Toxicity = hepatobiliary (DLT) and GI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

What is the MOA of verdinexor (Laverdia-ca1) (Sadowski BMC 2018) **committee member**

A

oral selective inhibitor of nuclear export (SINE) that transiently binds to XPO1 in a slowly reversible manner

XPO1 (exportin 1) is one way neoplastic cells move key tumor suppressor proteins and growth regulatory proteins from nucleus to cytoplasm (and make them therefore inactive)

XPO1 inhibition forces the nuclear retention of key TSP and GRP such as p53, p21, pRB, FOXO and NF-κB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

What was the ORR to Levardia (KPT-335/verdinexor) in dogs with LSA? (Sadowski BMC 2018) **Committee member**

A

ORR = 37%

Higher for dogs with Tcell LSA (71%)

48
Q

What was the ORR, mPFS and OST for dogs with b-cell LSA treated with dox/pred +/- L-spar? (Al-Nadaf BMC 2018)

A

ORR 84%

mPFS 147d (4.9mo)

OST 182d (6mo), 1yr survival 23%

49
Q

What was the ORR DFI and OST to LOPP chemotherapy for dogs with naive T cell LSA (Brown VCO 2018) Also, what was the protocol for this LOPP?

A

ORR 97% (CR 90%)

mDFI 176d (5.9mo)

OST 323d (10.8mo)

day 0 vinc

day 1 CCNU

days 2-12 procarb

repeat q4wks

50
Q

What was the difference in mPFI for L-CHO and L-CHOP in dogs with nodal LSA? (Childress JAVMA 2016)

A

L-CHO 142.5d (4.75mo)

L-CHOP 292d (9.7mo)

No stat diff but likely underpowered

More serious, but not sig, AE in L-CHO

51
Q

Of dogs that relapsed with LSA during CHOP, what drug(s) was it most commonly after? (Wang Vet J 2016)

A

Cyclophosphamide (24/41 dogs = 58%)

then vinc (9/41 22%)

then dox (5/41 12%)

52
Q

CCNU cLSA review - what are the MSTs for dogs w/o treatment vs. with CCNU-based protocol? What combinations with CCNU have been used? (Laprais BMC 2017)

A

w/o 3-5mo

CCNU protocols overall 6mo

CCNU + retinoids 11mo

CCNU/L-spar 9mo

CCNU/pred = 4mo

53
Q

What was the ORR for dogs with multicentric LSA treated with SQ or IM bleo? (Smith JAAHA 2017)

A

1/10 had PR (10%) but died 24d later from unrelated dz

54
Q

What is RAB and what is its MOA? (Thamm JVIM 2017)

A

RAB = double prodrug of nucleotide analog 9-(2-phosphonylmethoxyethyl) guanine (PMEG); selectively delivers PMEG + its active phosphorylated metabolite (PMEGpp) to lymphoid cells

Cytotoxic activity mediated by PMEG/PMEGpp is by inhibition of nuclear DNA polymerases alpha, delta, and epsilon.

55
Q

What was the trial design for alternating RAB/dox in dogs with naive LSA and what was the protocol for treatment? (Thamm JVIM 2017)

A

Open-label, multicenter prospective clinical trial

RAB 1.0mg/kg IV weeks 0, 6, and 12) Dox 30mg/m2 IV weeks 3, 9 and 15

56
Q

What was the ORR and mPFI for dogs with naive LSA treated with alternating RAB/Dox? (Thamm JVIM 2017)

A

ORR 84% (CR 68%, PR 16%)

mPFI 194d (6.5mo)

PFI for CR = 216d (7.2mo)

PFI for PR = 63d (2.1mo)

57
Q

What were the AEs reported for alternating RAB/DOX for dogs with naive LSA? (Thamm 2017)

A

Most mild to moderate & self-limiting, GI and heme most common

13 (24%) had derm AEs

2 dogs had grade 5 pulm fibrosis (3.7%)

58
Q

What is flavopiridol? (Ema VCO 2016)

A

Cyclin-dependent kinase (CDK) inhibitor

59
Q

What was the effect of flavopiridol in canine LSA cell lines (Ema VCO 2016)

A

Profound cell death via apoptosis via inhibition of Rb phosphorylation +/- CDK4 and 6 inhibition

60
Q

What is the VELCAP-TSC protocol? (Goodman Vet J 2016)

A

wk 1 Vinc + Lspar + pred

2: Vinc pred

3 doxo or mito pred

4 l-spar pred

5 vinc/ctx/pred

6off

7 vinc/actino/pred/procarb

8 vinc/actino/pred/procarb

11 doxo/mito

14 vinc/ctx

16 and 19 ccnu

61
Q

What was the ORR for dogs with T-cell LSA w/ no prior therapy treated with VELCAP-TSC? What was prognostic for achieving a CR? (Goodman 2016)

A

ORR 72.9%

CR 64.3%, PR 8.6%

Dogs neutropenic at dx more likely to achieve CR

62
Q

What was the mPFS and mOST for dogs with T cell LSA treated with VELCAP-TSC as a first line therapy? What was prognostic for these (Goodman Vet J 2016)

A

mPFS 175d (5.83mo) - longer in dogs w/ CR

mOST 237d (7.9d) - longer in dogs w/ CR, shorter for boxers and substage b

30% survived > 1yr

63
Q

What was the rate of AEs in dogs treated with VELCAP-TSC for naive T cell LSA? (Goodman Vet J 2016)

A

GI in 91% of dogs, neutropenia in 90%

57% dose reductions, 41% hospitalized

64
Q

What is valspodar? (Ito F1000 Res 2015) **Borgatti**

A

selective inhibitor of ATP binding bassette B1 transporter - used in dogs with large bcell lsa

65
Q

What was the difference in CD34+/CD117+/CD133+ lymphoma progenitor cells in dogs treated with Valspodar + doxo vs. placebo + dox? (Ito F1000 Res 2015) **Committee member)

A

No difference in total progenitor cells in nodes or blood

No difference in outcome

Drug well tolerated

66
Q

What is the CHOP15 protocol for LSA? (Curran VCO 2015)

A

Vinc, ctx, dox, off, repeat (basically just no second vinc)

67
Q

What was the ORR, PFS and LSS for dogs with naive LSA treated with CHOP 15 (+/- Lspar) (Curran VCO 2015)

A

ORR 98% (77.6% CR)

PFS 176d (5.9mo)

Lymphoma-specific survival 311d (10.4mo)

68
Q

What were prognostic factors associated with PFS in dogs with LSA treated with CHOP15 (Curran VCO 2015)

A

substage, immunophenotype, hospitalization for adverse events, need for dose reduction, presence of neutrophilia at diagnosis, presence of anemia and experiencing a CR

69
Q

What was the ORR and duration of response to masitinib monotherapy in canine cLSA? (Holtermann VCO 2015)

A

CR in 20% (2/10), lasted median 85d

PR in 5 dogs, lasted median 60.5d

70
Q

What was the % of dogs treated with masitinib with KIT positivity in dogs with cLSA? What about SCF? (Holtermann VCO 2015)

A

KIT negative in all dogs

6/8 strong positive for CSF

71
Q

What was or was not significantly correlated with PFI or OS in dogs treated with CHOP15 for multicentric LSA? (Burton VCO 2013)

A

Dogs w/ 2+ treatment delays had significantly prolonged survival (284d v 74d) and os (414d and 183d)

Dose intensity did NOT correlated with outcome

72
Q

What was the conclusion from the Zandveliet vet J 2013 study looking at CHO vs. CHOP?

A

No difference in initial response rates, DFI, rescue response and DFI, MST and AE for both groups

73
Q

What are the response rates to doxo for dogs with B vs. T cell LSA? (Beaver JAVMA 2010)

A

B cell 100%

T cell 50%

74
Q

What was the ORR to L-spar + MOPP in dogs with T cell and/or hypercal LSA? (Brodsky JVIM 2009) PFS? What were the AEs like?

A

ORR 98%

PFS 189d (6.3mo)

OST 270d (9mo)

20% required hospitalization due to AEs; 80% had GI AEs

75
Q

What was the ORR and median duration of response for dogs with cLSA treated with 70mg/m2 CCNU? (JVIM 2006 WIlliams)

A

ORR 78% (CR 17%, PR 61%)

median duration 106d. - if CR, not reached, if PR 88d

76
Q

What was the rate of AEs for dogs with cLSA treated with 70mg/m2 CCNU? (Williams JVIM 2006)

A

Myelosuppression 29%

GI22%

Liver 86% - ALT 47%, 5% grade 4

77
Q

What was the ORR and median duration of response for dogs with cLSA treated with 60mg/m2 CCNU? (Risbon JVIM 2006)

A

ORR 83%

Median duration 94d.

78
Q

What was the rate of elevated liver enzymes in dogs with cLSA treated with 60mg/m2 CCNU? (Risbon JVIM 2006)

A

3/46 = 6.5%

79
Q

What was the response rate for dogs with T cell LSA treated with CHOP? remission duration and OST? what was prognostic for OST?

A

RR = 95%

remission duration 146d (4.9mo)

OST 235d (7.8mo)

Thrombocytopenia at presentation sig long OST (323 vs 212)

80
Q

Was consolidation with half body RT or CCNU/MOPP after 8 weeks of CHOP benefical in outcome for dogs with LSA? (Rassnick JVIM 2007)

A

No difference in outcome between groups (historic CHOP group actually longest median first remission at 307d vs CCNU/MOPP at 274d, and HBRT 209 days

81
Q

What is the COAP protocol and what was used for maintenance chemo after finishing? Was it better than CHOP? (Hosoya JVIM 2007)

A

COAP = cytoxan, vinc, cytosar, pred; maint with LMP (lekeran, methotrexate, pred)

CHOP better - longer remissions; conclusion = including dox in chemo decreased risk of relapse and death

82
Q

What is the VCAA protocol for LSA? (Marconato VCO 2008)

A

Vinc, ctx, dox, lspar

83
Q

Was the addition of cytosar beneficial to VCAA in dogs with stage V LSA (bone marrow)? (Marconato VCO 2008)

A

Yup - CR in 8/9 in group with cytarabine, only 2/8 in VCAA w/o cytarabine

MST for VCAA+cytarabine = 243d vs. 72.5d for vcaa alone

84
Q

Was there a difference in PFI or OST for dogs treated with doxo + ctx given over three days vs. dogs treated with doxo + placebo for LSA? (Lori VCO 2010)

A

No stat sig difference but numerically ctx dogs did better

PFI: ctx = 246d (8.2mo) vs placebo = 169d (5.6mo)

OST ctx = 423d (14.1mo) vs placebo = 295d (9.8mo)

85
Q

Was there a difference in duration of first remission, survival time or response rate for dogs treated with CHOP w/ or w/o l-spar? (MacDonald JVIM 2005)

A

Nope, all similar between both groups

86
Q

What was the RR and MST for dogs with GI LSA with VELCAP-SC? (Rassnick JVIM 2009)

A

RR 56% ( 50% CR, 5% PR)

MST 77d.

87
Q

What was prognostic for dogs with GI LSA treated with VELCAP-SC for GI LSA? (Rassnick JVIM 2009)

A

Nonresponders (MST 10 vs 117d)

diarrhea (70 vs. 700d)

88
Q

What was the TTR and OST for dogs treated with Epirubicin instead of doxo in CHOP? (Elliott VCO 2012)

A

TTR 216d (7.2mo) , OST 342d (11.4mo)

Similar tox and outcome to CHOP with doxo

89
Q

What was the median remission and MST for dogs treated with CHOP-MA for LSA? What did this protocol involve? (Daters VCO 2010)

A

Median remission 302d (10mo), MST 622d (20.7mo)

Initial 18wk modified L-CHOP (no second vinc + varied in weeks off after doxo) then maintenance phase of vinc/cytoxan/mito given q3wk until week 57 thn consolidation phase - lpsar, cytoxan vinc cytoxan (total 60wk treatment =15mo of tx)

90
Q

What is ABT-751? (Silver JVIM 2012)

A

Oral anti-mitotic agent that targets tubule polymerization

91
Q

What was the max tolerated dose and response rate/duration for dogs with either naive or relapsed LSA treated with ABT-751? (Silvwer JVIM 2012)

A

Max dose = 350mg/m2 PO daily - vom/dia = DLT

ORR 20%, duration 21-111d

92
Q

What was the response rate, duration and MST for dogs with LSA treated with CCNU/pred as first line therapy? (Sauerbrey JAVMA 2007)

A

9/17 response (53%), duration 39d

MST 111d (3.7mo)

Females and higher total CCNU dose = longer DFI

93
Q

What was the rate dose reduction and treatment delays for a dose-intensified CHOP for canine LSA? (Sorenmo VCO 2010)

A

Vinc/ctx given same day

high tox - 53% needed DR, 45% but both associated with longer TTP and OS

94
Q

How did the pharmacokinetics of Ctx given IV or PO compare? (Warry JVIM 2011)

A

Drug exposure higher after IV but exposure toa ctive metabolite (4-hydroxycyclophosphamide) same with either route

95
Q

What was the objective response rate to gemcitabine for canine LSA? (Turner JVIM 2006)

A

No responses seen

96
Q

What was the ORR and OST for dogs treated with intermittent single-agent doxo (3 doses q2 until CR then monitoring and retx w/dox) (Higginbotham JAAHA 2013) **Committee member**

A

ORR 78%

OST 169.5d (5.7mo) - similar to normal admin of single agent doxo

97
Q

What dosing for CCNU/CTX combination treatment is recommended for dogs with LSA based on tolerability? (Rassnick JAAHA 2014)

A

CCNU 60mg/m2 day 0

CTX 250mg/m2 divided day 0-4

q4wks

98
Q

What was the RR and time to discontinuing therapy for DMAC as rescue (usually after CEOP)? (Smallwood VCO 2019)

A

RR 35%

TTD longer for CR (62d) than PR (32d)

Lower RR and duration than previous DMAC reports

99
Q

What was the RR and time to discontinuing treatment for dogs treated with LPP as rescute (LOPP w/o vinc) (Tanis VCO 2018)

A

RR 61% (half CR half PR)

TTD longer for CR (84d) vs. PR (58d)

100
Q

What was the ORR for dogs treated with bleo/cytosar for relapse LSA? (Batschinski JAAHA 2018)

A

ORR 36.8%, all PRs

101
Q

What was the ORR and PFI for dogs treated with RAB for relapsed LSA (most after dox-based protocols) (Saba VCO 2018)

A

ORR 74%, CR 45%

PFI 108d; responders 172d, CRs 203d (6.8mo)

102
Q

Was there a difference in repsonse or AEs for dogs treated with RAB at 0.82mg/kg vs. 1mg/kg for relapsed LSA (Saba VCO 2018)

A

No difference in outcome or toxicity

103
Q

What was the overall clinical benefit of oral melphalan for treatment of relapsed LSA in dogs? (Mastomauro VCO 2018)

A

31.6% had clinical benefit - PR or SD

Most treated with digh dose protocol (median 19.4mg/m2) and most had concurrent roids

104
Q

Was TMZ vs. TMZ/doxo more effective as a rescue protocol for dogs with LSA? (Treggiari VCO 2017)

A

Trick question - they were similar; difference = doxo/TMZ group had higher toxicity (63% vs. 46%)

overall MST = 40d.

105
Q

What was the ORR and MST for dogs treated with VBL as a second rescue agent for LSA? What about dosing and toxicity? (Lenz JSAP 2016) **committee member**

A

ORR = 25%, SD 45%

Dose of VBL median 2.6mg/m2, G3/4 neutropenia in 25%

MST 45d

106
Q

What was the response rate for dogs with relapsed or refractory LSA to carbo alone vs. carbo + cytarabine? (Gillem VCO 2015)

A

Response rate for combination 28.6%; carbo alone 0%

Thrombocytopenia and neutropenia common with combination

107
Q

What was the CR rate and median DFI for actinomycin + pred as a rescue for canine LSA? (Bannink JAVMA 2008)

A

CR 41%, DFI 129d (4.3mo)

108
Q

Was there a significant difference in CCNU/L-spar as a rescue protocol for canine LSA when L-spar was given with every dose of CCNU vs. just with the first 2 doses of CCNU? (Saba JVIM 2009 and 2007)

A

No difference

Every dose: ORR 77%, TTP 70d

First 2 doses: ORR 87%, TTP 63d.

109
Q

What was the rate of CR and duration of response for combination CCNU/DTIC as a rescue for canine LSA (Flory JVIM 2008)

A

CCNU 40mg/m2 followed by 5hr IV infusion of DTIC at 600mg/m2

23% CR, duration 83d

110
Q

What was the ORR and median PFI fod dogs treated with dacarbazine as a single agent as a rescue protocol for LSA? What was the dosing and tox? (Griessmayr JVIM 2009)

A

800-1000mgm2 q2-3wks over 4-5hrs

ORR 35%, median PFI 43d

Mild GI tox, thrombocvytopenia 7-14d post-tx

111
Q

What was the remission rate and median remission duration of DMAC (Alvarez JVIM 2006)

A

72% remission, 44% were CR

Duration 61d

112
Q

What was the ORR and median duration of response for BOPP vs. LOPP as rescues for canine LSA? What was a significant toxicity reported in this paper? (LeBlanc VCO 2006)

A

BOPP - 50% response, duration 129-140d

LOPP 52% response, duration 84-112d

13% treatment related mortality - 9% for LOPP

113
Q

What was the ORR and OST for dogs treated with the U of F LOPP protocol as a rescue for LSA? What was different about this compared to previously reported LOPP? (Fahey JAVMA 2011)

A

Vinc on d. 1 and 14 (vs. 0 and 7) –> less tox

ORR 61%, duration of response 84d

OST 290d

114
Q

What was the ORR and median duration of MPP as a rescue for canine LSA? (Northrup VCO 2009)

A

ORR 34%, median 56d

115
Q

What was the ORR and median duration of response and OST for dogs treated with MOMP (melphalan instead of procarb) for relapsed LSA? (Back VCO 2015) **Committee member**

A

ORR 51.1%

median duration 56d

OST 183d

116
Q

What was the rate of hospitalization and mortality related to MOPP as a rescue for canine LSA? (Rassnick JVIM 2002)

A

13% hospitalized, 2/117 mortality due to treatment (1.7%)

31% CR (duration 63d), 34% PR (duration 47d)

117
Q
A

Oncology Boards (26 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions